Comparison between the effect of omeprazole and rabeprazole on the antiplatelet action of clopidogrel

Circulation Journal

Volumn 74, Issue 10, 2010, Pages 2187-2192

  Siriswangvat, Suksiri ^a   Sansanayudh, Nakarin ^b   Nathisuwan, Surakit ^c   Panomvana, Duangchit ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b PHRAMONGKUTKLAO HOSPITAL   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Clopidogrel; Omeprazole; Platelet aggregation; Rabeprazole

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; OMEPRAZOLE; RABEPRAZOLE;

ADULT; ANTICOAGULATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; DRUG RESPONSE; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADENOSINE DIPHOSPHATE; AGED; ASPIRIN; CORONARY ARTERY DISEASE; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 77958069235     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0913     Document Type: Article

References (29)

1. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FKL, Furberg CD, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A report of the American college of cardiology foundation task force on clinical expert consensus documents. Circulation 2008; 118: 1894-1909.
2. Brandt J, Close S, Iturria S, Payne C, Farid N, Ernest C, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007; 5: 2429-2436.
3. Hulot J-Sb, Bura A, Villard E, Azizi M, Remones Vr, Goyenvalle C, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108: 2244-2247.
4. Ishizaki T, Horai Y. Review article: Cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13: 27-36.
5. Gilard M, Arnaud B, Cornily J-C, Gal GL, Lacut K, Calvez GL, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. J Am Coll Cardiol 2008; 51: 256-260.
6. Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008; 48: 475-484.
7. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009; 157: 148.e1-e5.
8. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-944.
9. FDA Approved Drug Products. Product on application of rabeprazole sodium. http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20973S013lbl.pdf (accessed 18 May, 2009).
10. Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004; 32: 821-827.
11. Müller I, Besta F, Schulz C, Li Z, Massberg S, Gawaz M. Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation 2003; 108: 2195-2197.
12. Serebruany VL, Midei MG, Malinin AI, Oshrine BR, Lowry DR, Sane DC, et al. Absence of interaction between atorvastatin or other statins and clopidogrel. Arch Intern Med 2004; 164: 2051-2057.
13. Angiolillo DJ, Alfonso F. Clopidogrel-Statin interaction. J Am Coll Cardiol 2007; 50: 296-298.
14. Hong SJ, Park JY, Kim KA, Ahn CM, Park JS, Kim YH, et al. Comparison of low vs moderate dose of atorvastatin in clopidogrel resistance after coronary stenting in Korean patients with acute coronary syndrome. Circ J 2009; 73: 1111-1118.
15. Erlinge D, Varenhorst C, Braun OÖ, James S, Winters KJ, Jakubowski JA, et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added Ex Vivo. J Am Coll Cardiol 2008; 52: 1968-1977.
16. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742-1750.
17. Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study. Circulation 2007; 115: 1-8.
18. Ahn Y, Jeong MH, Jeong JW, Kim KH, Ahn TH, Kang WC, et al. Randomized comparison of cilostazol vs clopidogrel after drugeluting stenting in diabetic patients. Circ J 2008; 72: 35-39.
19. Hoshino K, Horiuchi H, Tada T, Tazaki J, Nishi E, Kawato M, et al. Clopidogrel resistance in Japanese patients scheduled for Percutaneous Coronary Intervention. Circ J 2009; 73: 336-342.
20. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312-2317.
21. Cuisset T, Frere C, Quilici J, Morange PE, Nait-Saidi L, Carvajal J, et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 2006; 48: 1339-1345.
22. Cuisset T, Frere C, Quilici J, Morange PE, Nait-Saidi L, Mielot C, et al. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thromb Haemost 2007; 97: 282-287.
23. Patel P, Gonzales R, Dokainish H, Lakkis N. Impact of adenosine diphosphate and calcium chelation on platelet aggregation testing in patients receiving clopidogrel therapy. J Am Coll Cardiol 2006; 47: 464-465.
24. Giustia B, Goria AM, Marcuccia R, Saracinia C, Sestinia I, Panicciaa R, et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 +12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenetics Genom 2007; 17: 1057-1064.
25. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008; 51: 1925-1934.
26. Malek LA, Kisiel B, Spiewak M, Grabowski M, Filipiak KJ, Kostrzewa G, et al. Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J 2008; 72: 1165-1169.
27. Tassaneeyakul W, Mahatthanatrakul W, Niwatananun K, Na-Bangchang K, Tawalee A, Krikreangsak N, et al. CYP2C19 genetic polymorphism in Thai, Burmese and Karen populations. Drug Metab Pharmacokinet 2006; 21: 286-290.
28. Tassaneeyakul W, Tawalee A, Tassaneeyakul W, Kukongviriyapan V, Blaisdell J, Goldstein JA, et al. Analysis of the CYP2C19 polymorphism in a North-eastern Thai population. Pharmacogenetics 2002; 12: 221-225.
29. Yamada S, Onda M, Kato S, Matsuda N, Matsuhisa T, Yamada N, et al. Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations. J Gastroenterol 2001; 36: 669-672.